Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Alpelisib × 30 days × Clear all

Phase

Status

Active not recruiting 5 Recruiting 3 Terminated 1 Completed 1 Available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 13 Cisplatin 6 Carboplatin 5 atezolizumab 4 Paclitaxel 4 tazemetostat 3 Surveys and Questionnaires 3 Radiotherapy 3 Practice Guidelines as Topic 3 Nivolumab 3 Ipilimumab 3 Gemcitabine 3 Bevacizumab 3 venetoclax 2 trametinib 2 olaparib 2 fludarabine 2 cabozantinib 2 binimetinib 2 Standard of Care 2 Saline Solution 2 Rituximab 2 Radiosurgery 2 Pemetrexed 2 Oxaliplatin 2 Melphalan 2 Injections 2 Granulocyte Colony-Stimulating Factor 2 Fluorouracil 2 Filgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04251533 2026-04-03

EPIK-B3

Novartis

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡